Replies to post #216789 on Anavex Life Sciences Corp (AVXL)

[Talon38]

George...The Insight Report is one of the most exhaustive articles on Alzheimer's and highlights your captured excerpt under the topic of Mitochondrial Dysfunction. The Report's positive mention of Anavex 2-73 as an effective sigma-1/ muscarinic receptor antagonist is one of the few drugs positively cited. Good read.

-----

https://www.biospace.com/article/insight-report-potential-therapeutic-targets-for-alzheimer-s/?utm_campaign=GenePool&utm_source=hs_email&utm_medium=email&utm_content=78680898&_hsenc=p2ANqtz-8WLjbWCfbbiGM6fHiwn46DUxiDP5SZ7FZy_dt1eMWgVJnhNPTsjnceM-EEQPDOHUcNSFCYIS0EjSt2Ct5xLZncScDKdg&_hsmi=78680898

[Investor2014]

The author got this bit wrong

A mixed sigma-1/muscarinic receptor antagonist (ANAVEX 2-73)

[georgejjl]

Correction

The sigma-1 and muscarinic receptors have also been implicated in neurodegenerative diseases by acting as general modulators of many cellular mechanisms, including microglial regulation, mitochondrial dysfunction, oxidative damage, and endoplasmic reticulum stress. A mixed sigma-1/muscarinic receptor agonist (ANAVEX 2-73) has been shown to prevent mitochondrial dysfunction (and the resulting oxidative damage) and reduce tau hyperphosphorylation and beta-amyloid accumulation in the brains of Alzheimer’s mouse models.

https://www.biospace.com/article/insight-report-potential-therapeutic-targets-for-alzheimer-s/

Good luck and GOD bless,